Redefining the Ki-67 Index Stratification for Low-Grade Pancreatic Neuroendocrine Tumors: Improving Its Prognostic Value for Recurrence of Disease

Background The Ki-67 index is an established prognostic marker for recurrence after resection of pancreatic neuroendocrine tumors (PanNETs) that groups tumors into three categories: low grade (< 3%), intermediate grade (3–20%), and high grade (> 20%). Given that the majority of resected PanNET...

Full description

Saved in:
Bibliographic Details
Published inAnnals of surgical oncology Vol. 25; no. 1; pp. 290 - 298
Main Authors Lopez-Aguiar, Alexandra G., Ethun, Cecilia G., Postlewait, Lauren M., Zhelnin, Kristen, Krasinskas, Alyssa, El-Rayes, Bassel F., Russell, Maria C., Sarmiento, Juan M., Kooby, David A., Staley, Charles A., Maithel, Shishir K., Cardona, Kenneth
Format Journal Article
LanguageEnglish
Published Cham Springer International Publishing 2018
Springer Nature B.V
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Background The Ki-67 index is an established prognostic marker for recurrence after resection of pancreatic neuroendocrine tumors (PanNETs) that groups tumors into three categories: low grade (< 3%), intermediate grade (3–20%), and high grade (> 20%). Given that the majority of resected PanNETs have a Ki-67 less than 3%, this study aimed to stratify this group further to predict disease recurrence more accurately. Methods The Ki-67 index was pathologically re-reviewed and scored by a pathologist blinded to all other clinicopathologic variables using tissue microarray blocks made in triplicate. All patients who underwent curative-intent resection of non-metastatic PanNETs at a single institution from 2000 to 2013 were included in the study. The primary outcome was recurrence-free survival (RFS). Results Of 113 patients with well-differentiated PanNETs resected, 83 had tissue available for pathologic re-review. The Ki-67 index was lower than 3% for 72 tumors (87%) and between 3 and 20% for 11 tumors (13%). Considering only Ki-67 less than 3%, the tumors were further stratified by Ki-67 into three groups: group A (< 1%, n  = 43), group B (1–1.99%, n  = 23), and group C (2–2.99%, n  = 6). Compared with group A, groups B and C more frequently had advanced T stage (T3: 44% and 67% vs 12%; p  = 0.003) and lymphovascular invasion (50% and 83% vs 23%; p  = 0.007). Groups B and C had similar 1- and 3-year RFS, both less than group A. After combining groups B and C, a Ki-67 of 1–2.99% was associated with decreased RFS compared with group A (< 1%). This persisted in the multivariable analysis (hazard ratio [HR] 8.6; 95% confidence interval [CI] 1.0–70.7; p  = 0.045), with control used for tumor size, margin-positivity, lymph node involvement, and advanced T stage. Conclusions PanNETs with a Ki-67 of 1–2.99% exhibit distinct biologic behavior and earlier disease recurrence than those with a Ki-67 lower than 1%. This new stratification scheme, if externally validated, should be incorporated into future grading systems to guide both surveillance protocols and treatment strategies.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1068-9265
1534-4681
DOI:10.1245/s10434-017-6140-8